BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive Clinical Trial

Official title:

Randomized, Placebo-controlled, Double-blind Within Dose Groups, Multiple Rising-dose Study to Evaluate Safety, Tolerability, and PK of Oral BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With COPD Associated With Chronic Bronchitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01958008
• Other study ID #: 1314.5
• Secondary ID: 2012-005451-16
• Status: Completed
• Phase: Phase 1
• First received: October 1, 2013
• Last updated: August 6, 2014
• Start date: September 2013
• Est. completion date: May 2014

Study information

• Verified date: August 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The main objective of the current trial is to investigate safety, tolerability and pharmacokinetics of BI 113608 in COPD patients with symptoms of chronic bronchitis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 80 Years

Eligibility

Inclusion criteria:

1. All patients must sign an informed consent consistent with ICH-GCP guidelines and local legislations prior to any study-related procedures, which includes medication washout and restrictions.

2. All patients must have a documented diagnosis of COPD according to GOLD 2013.

3. Post-bronchodilator 50% = FEV1 < 80% of predicted at screening visit.

4. Post-bronchodilator FEV1/FVC <70% at screening visit.

5. Patients must have a history of chronic bronchitis as defined by symptoms of cough and sputum production on most days during at least three months for the past two consecutive years.

6. CAT Questionnaire at screening: a score of at least one for both cough (1st question) and sputum (2nd question).

7. Males and females between 40 and 80 years (inclusive) of age, on the day of patient´s signature of informed consent.

8. Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded.

9. Patients must be able to perform technically acceptable pulmonary function tests (body plethysmography, forced spirometry and DLCO measurement).

10. Females must be of non-childbearing potential. Women of nonchildbearing potential are defined as those who have undergone bilateral ovariectomy, bilateral salpingectomy or hysterectomy. If so, documentation confirming the surgical procedure must be available on the patient's source documents. A woman is also presumed to be infertile due to natural causes if she has been amenorrheic for more than 24 months. In estionable cases, a blood analysis of FSH and estradiol, which indicates the postmenopausal status according to the central laboratory ranges for postmenopausal females, is considered confirmatory.

Exclusion criteria:

1. Significant pulmonary disease other than COPD or other medical conditions* (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator, result in the any of the following:

1. Put the patient at risk because of participation in the study,

2. Influence the results of the study,

3. Cause concern regarding the patient's ability to participate in the study. (*e.g. cardiac, gastro-intestinal, hepatic, renal, metabolic, dermatologic, neurological, haematological, oncological and psychiatric; history of relevant orthostatic hypotension, fainting spells or blackouts; current chronic or relevant acute infections.)

2. Patients with any lung disease other than COPD (e.g. asthma, interstitial lung disease (ILD), cystic fibrosis, active tuberculosis, post-TB syndrome, clinically evident bronchiectasis, with a history of thoracotomy with pulmonary resection).

3. Patients with clinically relevant abnormal haematology, blood chemistry, or urinalysis at screening visit (Visit 1), if the abnormality defines a relevant disease as defined in exclusion critrion number 1.

4. All patients with a serum glutamate oxaloacetate transferase (SGOT) or serum glutamic pyruvic transaminase (SGPT) or total bilirubin higher than 1.5-fold ULN or serum creatinine higher than normal at Visit 1 (and at all repeated tests, if applicable) will be excluded regardless of the clinical condition. Laboratory evaluation can be repeated maximum two times.

5. A malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years (patients with treated basal cell carcinoma are allowed).

6. Patients with current relevant psychiatric disorders based on the investigator´s judgement.

7. Patients with any respiratory infection (e.g. common cold, sinusitis, etc.) or COPD exacerbation within the six weeks prior to the screening visit (Visit 1) or between screening visit and randomization.

8. Patients with a history of two or more moderate or severe COPD exacerbations per year within the last two years.

9. Patients with a history of and/or active significant alcohol or drug abuse. See exclusion criterion number 1.

10. Patients who are being treated with non-permitted concomitant medication.

11. Patients with a recent history (i.e. three years or less) of heart failure or patients with any cardiac arrhythmia requiring drug therapy.

12. Patients who have previously been randomised in this trial.

13. Current participation in another clinical trial (as defined in the ICH Harmonised Tripartite Guideline for Good Clinical Practice (GCP)).

14. Donation of more than 100 mL of blood within the past four weeks prior to screening.

15. A history of additional risk factors for torsade-de-pointes (e.g., heart failure, relevant hypokalemia, family history of Long QT Syndrome).

16. Pregnant or nursing women.

17. Gastrointestinal tract surgery that might affect absorption and elimination of drugs.

18. Patients with known hypersensitivity / allergy to the investigational medicinal product (IMP) or its excipients.

19. Male Patients who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until two months after study completion.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bronchitis
• Bronchitis, Chronic
• Chronic Disease
• Lung Diseases
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Placebo to BI 113608 high dose b.i.d.
Film-coated tablet
• Placebo to BI 113608 low dose b.i.d.
Film-coated tablet
• BI 113608 high dose b.i.d.
Film-coated tablet
• Placebo to BI 113608 medium dose b.i.d.
Film-coated tablet
• BI 113608 low dose b.i.d.
Film-coated tablet
• BI 113608 medium dose b.i.d.
Film-coated tablet

Locations

Country	Name	City	State
Germany	1314.5.49003 Boehringer Ingelheim Investigational Site	Berlin
Germany	1314.5.49005 Boehringer Ingelheim Investigational Site	Frankfurt
Germany	1314.5.49001 Boehringer Ingelheim Investigational Site	Gauting
Germany	1314.5.49004 Boehringer Ingelheim Investigational Site	Großhansdorf
Germany	1314.5.49006 Boehringer Ingelheim Investigational Site	Lübeck
Germany	1314.5.49007 Boehringer Ingelheim Investigational Site	Mannheim

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of patients with drug-related adverse events		up to 7 weeks	No
Secondary	C max,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval tau)		4 weeks	No
Secondary	t max,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)		4 weeks	No
Secondary	AUC tau,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval tau)		4 weeks	No
Secondary	t 1/2,ss (terminal half-life of the analyte in plasma at steady state)		4 weeks	No
Secondary	R A,Cmax (Accumulation ratio of the analyte in plasma at steady state after multiple oral administration over a uniform dosing interval tau, expressed as ratio of C max at steady state and after single dose)		4 weeks	No
Secondary	R A,AUC (Accumulation ratio of the analyte in plasma at steady state after multiple dose administration over a uniform dosing interval tau, expressed as ratio of AUC at steady state and after single dose)		4 weeks	No